RT Journal Article
SR Electronic
T1 Increased Autotaxin levels in severe COVID-19, correlating with IL-6 levels, endothelial dysfunction biomarkers, and impaired functions of dendritic cells
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.07.30.21261361
DO 10.1101/2021.07.30.21261361
A1 Ioanna Nikitopoulou
A1 Dionysios Fanidis
A1 Konstantinos Ntatsoulis
A1 Panagiotis Moulos
A1 George Mpekoulis
A1 Maria Evangelidou
A1 Alice G. Vassiliou
A1 Vasiliki Dimakopoulou
A1 Edison Jahaj
A1 Stamatios Tsipilis
A1 Stylianos E. Orfanos
A1 Ioanna Dimopoulou
A1 Emmanouil Angelakis
A1 Karolina Akinosoglou
A1 Niki Vassilaki
A1 Argyris Tzouvelekis
A1 Anastasia Kotanidou
A1 Vassilis Aidinis
YR 2021
UL http://medrxiv.org/content/early/2021/07/31/2021.07.30.21261361.abstract
AB Autotaxin (ATX; ENPP2) is a secreted lysophospholipase D catalysing the extracellular production of lysophosphatidic acid (LPA), a pleiotropic signalling phospholipid. Genetic and pharmacologic studies have previously established a pathologic role for ATX and LPA signalling in pulmonary injury, inflammation, and fibrosis. Here, increased ENPP2 mRNA levels were detected in immune cells from nasopharyngeal swab samples of COVID-19 patients, and increased ATX serum levels were found in severe COVID-19 patients. ATX serum levels correlated with the corresponding increased serum levels of IL-6 and endothelial damage biomarkers, suggesting an interplay of the ATX/LPA axis with hyperinflammation and the associated vascular dysfunction in COVID-19. Accordingly, dexamethasone (Dex) treatment of mechanically ventilated patients reduced ATX levels, as shown in two independent cohorts, indicating that the therapeutic benefits of Dex include the suppression of ATX. Moreover, large scale analysis of multiple single cell RNAseq datasets revealed the expression landscape of ENPP2 in COVID-19 and further suggested a role for ATX in the homeostasis of dendritic cells, that exhibit both numerical and functional deficits in COVID-19. Therefore, ATX has likely a multifunctional role in COVID-19 pathogenesis, worth of suggesting that its pharmacological targeting might represent an additional therapeutic option.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work has been co‐financed by the European Union and Greek national funds through the Operational Program Competitiveness, Entrepreneurship and Innovation, under the call Research/Create/Innovate (project code: T1EDK/0049; recipient VA). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Evangelismos Hospital Research Ethics Committee (# 170/24-4-2020). The study was approved by the University Hospital of Patras Research Ethics Committee (# 216/08-05-2020).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are reported within the manuscript.